{"filing":{"accession_number":"0001193125-26-429129","cik":"0002153598","ticker":null,"company_name":"Frazier Life Sciences Acquisition Corp. II","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-15","primary_document":"d430914d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2153598/000119312526429129/d430914d8k.htm"},"events":[{"id":37355,"run_id":34433,"accession_number":"0001193125-26-429129","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"This disclosure reports the consummation of an IPO and concurrent private placement by a blank-check SPAC (Frazier Life Sciences Acquisition Corp. II), with $75 million in gross IPO proceeds and $3 million in private placement proceeds placed in trust. While the IPO itself is a capital-raising event, the 8-K Item 8.01 disclosure focuses on post-closing trust account mechanics and financial position rather than the IPO announcement itself (which would typically be Item 2.01 or a press release). The audited balance sheet and detailed trust account provisions suggest this is a routine post-IPO disclosure of financial position and governance structure for a newly public SPAC, making it operational/financial in nature but not fitting neatly into a specific event category.","company_name":"Frazier Life Sciences Acquisition Corp. II","ticker":null,"filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":42042,"accession_number":"0001193125-26-429129","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This disclosure reports the consummation of an IPO and concurrent private placement by a blank-check SPAC (Frazier Life Sciences Acquisition Corp. II), with $75 million in gross IPO proceeds and $3 million in private placement proceeds placed in trust. While the IPO itself is a capital-raising event, the 8-K Item 8.01 disclosure focuses on post-closing trust account mechanics and financial position rather than the IPO announcement itself (which would typically be Item 2.01 or a press release). The audited balance sheet and detailed trust account provisions suggest this is a routine post-IPO disclosure of financial position and governance structure for a newly public SPAC, making it operational/financial in nature but not fitting neatly into a specific event category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T21:25:54.650385+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42042,"accession_number":"0001193125-26-429129","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This disclosure reports the consummation of an IPO and concurrent private placement by a blank-check SPAC (Frazier Life Sciences Acquisition Corp. II), with $75 million in gross IPO proceeds and $3 million in private placement proceeds placed in trust. While the IPO itself is a capital-raising event, the 8-K Item 8.01 disclosure focuses on post-closing trust account mechanics and financial position rather than the IPO announcement itself (which would typically be Item 2.01 or a press release). The audited balance sheet and detailed trust account provisions suggest this is a routine post-IPO disclosure of financial position and governance structure for a newly public SPAC, making it operational/financial in nature but not fitting neatly into a specific event category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T21:25:54.650385+00:00","company_name":"Frazier Life Sciences Acquisition Corp. II","ticker":null,"filing_date":"2026-10-22"}]}